Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03763253 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms

Study acronym: IP2-ATLANTA
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 7, 2025 (before its estimated August 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 399 to confirmed 433 · Study description revised · Site details revised at 21 of 21 sitesv7 Show 3 more changesShow less
    • Enrollment target: estimated 399 to confirmed 433
    • Study description revised
    • Site details revised at 21 of 21 sites

    See this version in full on ClinicalTrials.gov ↗

  2. Enrollment target: 918 to 399 Primary completion date: Mar 1, 2023 to Aug 31, 2026 · Study sites: 14 to 21 · Completion date: Mar 1, 2024 to Jan 31, 2027 · 2 morev6 Show 5 more changesShow less
    • Primary completion date: Mar 1, 2023 to Aug 31, 2026
    • Study sites: 14 to 21
    • Completion date: Mar 1, 2024 to Jan 31, 2027
    • Eligibility criteria revised
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites: 15 to 14v5
  4. Study sites: 16 to 15 Secondary endpoints: details revised at 5 of 5 entries · Study description shortened, about 130 words · Study title revised · 1 morev4 Show 4 more changesShow less
    • Secondary endpoints: details revised at 5 of 5 entries
    • Study description shortened, about 130 words
    • Study title revised
    • Eligibility criteria expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  5. Trial status: Not Yet Recruiting to Recruiting Study sites: 17 to 16 · Start date changed from estimate of Apr 1, 2019 to Apr 10, 2019v3 Show 2 more changesShow less
    • Study sites: 17 to 16
    • Start date changed from estimate of Apr 1, 2019 to Apr 10, 2019
  6. Start date: Jan 1, 2019 to Apr 1, 2019v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Local cytoreductive treatments for men with newly diagnosed metastatic prostate cancer in addition to standard of care treatment
Trial Details
NCT Number NCT03763253
Lead Sponsor Imperial College London
Collaborators: Wellcome Trust
Conditions Prostate Cancer, Metastatic Prostate Cancer
Enrollment 433 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov